Cargando…
Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals
INTRODUCTION: Subtle cognitive impairment (SCI) may appear before pathological changes surpass thresholds for abnormality. We aimed to investigate whether SCI could predict Alzheimer's pathologies and advancement. METHODS: A total of 816 cognitively normal individuals were enrolled to assess th...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158163/ https://www.ncbi.nlm.nih.gov/pubmed/34095433 http://dx.doi.org/10.1002/dad2.12198 |
_version_ | 1783699826817368064 |
---|---|
author | Shen, Xue‐Ning Kuo, Kevin Yang, Yu‐Xiang Li, Hong‐Qi Chen, Shi‐Dong Cui, Mei Tan, Lan Dong, Qiang Yu, Jin‐Tai |
author_facet | Shen, Xue‐Ning Kuo, Kevin Yang, Yu‐Xiang Li, Hong‐Qi Chen, Shi‐Dong Cui, Mei Tan, Lan Dong, Qiang Yu, Jin‐Tai |
author_sort | Shen, Xue‐Ning |
collection | PubMed |
description | INTRODUCTION: Subtle cognitive impairment (SCI) may appear before pathological changes surpass thresholds for abnormality. We aimed to investigate whether SCI could predict Alzheimer's pathologies and advancement. METHODS: A total of 816 cognitively normal individuals were enrolled to assess the longitudinal neuropathological and clinical correlates of baseline SCI, via linear mixed‐effects and Cox proportional‐hazard models. Cross‐lagged panel models were used in specific time waves. RESULTS: SCI individuals had a faster increase in brain amyloid burden and a higher risk of conversion. They also showed greater rates of cerebrospinal fluid (CSF) phosphorylated tau (p‐tau)(181) increase and glucose metabolism decrease. In addition, baseline SCI predicted worse clinical progression, whereas multi‐domain SCI advanced faster compared to the single domain group. DISCUSSION: Baseline SCI could be an imperative prediction indicator of clinical and pathological progression. It enables cognitive measures to be informative at a very early stage and provided objective criteria for high‐risk population screening. |
format | Online Article Text |
id | pubmed-8158163 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81581632021-06-03 Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals Shen, Xue‐Ning Kuo, Kevin Yang, Yu‐Xiang Li, Hong‐Qi Chen, Shi‐Dong Cui, Mei Tan, Lan Dong, Qiang Yu, Jin‐Tai Alzheimers Dement (Amst) Cognitive & Behavioral Assessment INTRODUCTION: Subtle cognitive impairment (SCI) may appear before pathological changes surpass thresholds for abnormality. We aimed to investigate whether SCI could predict Alzheimer's pathologies and advancement. METHODS: A total of 816 cognitively normal individuals were enrolled to assess the longitudinal neuropathological and clinical correlates of baseline SCI, via linear mixed‐effects and Cox proportional‐hazard models. Cross‐lagged panel models were used in specific time waves. RESULTS: SCI individuals had a faster increase in brain amyloid burden and a higher risk of conversion. They also showed greater rates of cerebrospinal fluid (CSF) phosphorylated tau (p‐tau)(181) increase and glucose metabolism decrease. In addition, baseline SCI predicted worse clinical progression, whereas multi‐domain SCI advanced faster compared to the single domain group. DISCUSSION: Baseline SCI could be an imperative prediction indicator of clinical and pathological progression. It enables cognitive measures to be informative at a very early stage and provided objective criteria for high‐risk population screening. John Wiley and Sons Inc. 2021-05-27 /pmc/articles/PMC8158163/ /pubmed/34095433 http://dx.doi.org/10.1002/dad2.12198 Text en © 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Cognitive & Behavioral Assessment Shen, Xue‐Ning Kuo, Kevin Yang, Yu‐Xiang Li, Hong‐Qi Chen, Shi‐Dong Cui, Mei Tan, Lan Dong, Qiang Yu, Jin‐Tai Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals |
title | Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals |
title_full | Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals |
title_fullStr | Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals |
title_full_unstemmed | Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals |
title_short | Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals |
title_sort | subtle cognitive impairment as a marker of alzheimer's pathologies and clinical progression in cognitively normal individuals |
topic | Cognitive & Behavioral Assessment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158163/ https://www.ncbi.nlm.nih.gov/pubmed/34095433 http://dx.doi.org/10.1002/dad2.12198 |
work_keys_str_mv | AT shenxuening subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals AT kuokevin subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals AT yangyuxiang subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals AT lihongqi subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals AT chenshidong subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals AT cuimei subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals AT tanlan subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals AT dongqiang subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals AT yujintai subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals AT subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals |